31 January 2012 - Sweden's Orexo AB (STO:ORX) and Janssen Pharmaceuticals Inc, a company of US Johnson & Johnson (NYSE:JNJ), announced their decision to end their research collaboration and licence agreement regarding the OX-CLI and OX-ESI programmes and a third, unnamed Janssen programme.<...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up